Adiposity Excess and Vertebral Fractures in Patients With Breast Cancer Taking Aromatase Inhibitors
Main finding · VF progressionResult — go to the resultAdjusted hazard ratio 2.00 95% CI 1.44–2.82Authors' conclusion
In this retrospective cohort study of patients with EBC receiving AIs, adiposity excess was identified as a novel fracture risk factor, whereas higher muscle mass was protective.
Study context
- Population
- Consecutive postmenopausal White women with early breast cancer (EBC) (stages I–III) receiving adjuvant aromatase inhibitors (AIs) with serial DXA, single referral center, September 2014–June 202469 (9.0%) with vertebral fracture (VF) progression
- Participants
- 769 women
- Exposure
- FM% >40.8% vs FM% ≤40.8%
- Outcome
- VF progression: new incident fractures and/or worsening by ≥1 Genant grade at a previously fractured vertebral level
Methodological detailssingle referral center, consecutive patients, joint model, extended Cox regression
- Single referral center
- Consecutive patients
- Joint model
- Extended Cox regression
Main finding
VF progression
Adjusted hazard ratio
2.00
95% CI 1.44–2.82
P < 0.001
FM% >40.8%vs FM% ≤40.8%
aHR 2.00 (95% CI 1.44–2.82); P < 0.001
As reported in the abstract
Observational data: associations, not effects.
Further findings
VF progression by higher appendicular lean mass index (ALMI)
| HR (95% CI) | P value | ||
|---|---|---|---|
| Higher ALMI | 0.38 (0.22–0.65) | P < 0.001 | |
| 0.20.5125Hazard ratio (log scale) |
VF progression by higher BMD
| HR (95% CI) | P value | ||
|---|---|---|---|
| Higher BMD | 0.79 (0.66–0.94) | P = 0.01 | |
| 0.512Hazard ratio (log scale) |
Original publication
Adiposity Excess and Vertebral Fractures in Patients With Breast Cancer Taking Aromatase Inhibitors. JAMA Netw Open. Published 1 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →